Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02119819 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT02119819: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by OPKO Health.
NCT02119819 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by OPKO Health. The registered enrollment target is 420 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02119819, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. All drugs will be given by an injection under the skin. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. Participants' involvement in the study is expected to last about 30 weeks.
Primary Outcome
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG LY2944876
- DRUG Exenatide extended-release
Study Locations (20)
California
- John Muir Physician Network Clinical Research Center - Concord
- Valley Endocrine, Fresno - Fresno
- National Research Institute - Los Angeles
- Desert Medical Group Inc - Palm Springs
- Artemis Institute for Clinical Research - San Diego
- Encompass Clinical Research - Spring Valley
Florida
- Meridien Research - Bradenton
- M & O Clinical Research, LLC - Fort Lauderdale
- Suncoast Research Group, LLC - Miami
- Suncoast Clinical Research - New Port Richey
- Compass Research - Oviedo
- Clinical Research of Central Florida - Winter Haven
Missouri
- Mercy Medical Research Institute - Springfield
- St John's Mercy Medical Center - St Louis
- Mercy Health Research - Washington
Hawaii
- University of Hawaii - Honolulu
- East West Medical Institute - Honolulu
Idaho
- Rocky Mountain Diabetes and Osteoporosis Center - Idaho Falls
Iowa
- Iderc, P.L.C. - Des Moines
Kansas
- Cotton O'Neil Diabetes and Endocrinology Center - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
What the finished NCT02119819 record still lists
NCT02119819 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02119819 names 20 study sites across 7 states, led by California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT02119819 about?
NCT02119819 is a clinical study titled "A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes". The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. All drugs will be given by an injection under the skin. Participants remain on stable doses of metfo...
What is the current status of trial NCT02119819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2014-04. Estimated completion is 2015-10.
What conditions does trial NCT02119819 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02119819?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), LY2944876 (DRUG), Exenatide extended-release (DRUG).
Who is sponsoring clinical trial NCT02119819?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02119819 being conducted?
This trial has 20 study locations across California, Florida, Hawaii, Idaho, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02119819's enrollment target sits among peer trials
420 89th of 348 higher than 260 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia